{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:14:36Z","timestamp":1780586076193,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01763-5","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:01:10Z","timestamp":1777842070000},"page":"3123-3138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05919082","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lin","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"El Mongy J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle","family":"Kurvits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Strodl","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-682X","authenticated-orcid":false,"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"issue":"5","key":"1763_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, et\u00a0al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"1763_CR2","first-page":"167","volume":"6","author":"AH M\u00f8ller","year":"2015","unstructured":"M\u00f8ller AH, Erntoft S, Vinding GR, Jemec GB. A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas. 2015;6:167\u201377.","journal-title":"Patient Relat Outcome Meas"},{"issue":"5","key":"1763_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/ijd.14864","volume":"59","author":"S AlQassimi","year":"2020","unstructured":"AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis \u2013 Comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59(5):566\u201371.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1763_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","volume":"84","author":"S Mehrmal","year":"2020","unstructured":"Mehrmal S, Uppal P, Nedley N, Giesey RL, Delost GR. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017. J Am Acad Dermatol. 2020;84(1):46\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1763_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, et\u00a0al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1763_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et\u00a0al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1763_CR7","first-page":"645","volume":"16","author":"A Nast","year":"2018","unstructured":"Nast A, Amelunxen L, Augustin M, et\u00a0al. S3 guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. JDDG. 2018;16(5):645\u201369.","journal-title":"JDDG"},{"issue":"Suppl 4","key":"1763_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1468-3083.2011.04060.x","volume":"25","author":"A Bewley","year":"2011","unstructured":"Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1763_CR9","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/jdv.15398","volume":"33","author":"AE Pink","year":"2019","unstructured":"Pink AE, Jalili A, Berg P, et\u00a0al. Rapid onset of action of calcipotriol\/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. J Eur Acad Dermatol Venereol. 2019;33(6):1116\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1763_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/jdv.15393","volume":"33","author":"A Jalili","year":"2019","unstructured":"Jalili A, Lebwohl M, Stein Gold L, et\u00a0al. Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. J Eur Acad Dermatol Venereol. 2019;33(4):709\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"S1","key":"1763_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jdv.17085","volume":"35","author":"A Jalili","year":"2021","unstructured":"Jalili A, Yosipovitch G. Fixed\u2010dose combination calcipotriol\/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life. J Eur Acad Dermatol Venereol. 2021;35(S1):20\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1763_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/1744666X.2020.1776116","volume":"16","author":"M Megna","year":"2020","unstructured":"Megna M, Cinelli E, Camela E, Fabbrocini G. Calcipotriol\/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data. Expert Rev Clin Immunol. 2020;16(6):599\u2013620.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"1763_CR13","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s13555-023-01024-9","volume":"13","author":"MC Fargnoli","year":"2023","unstructured":"Fargnoli MC, De Simone C, Gisondi P, Pellacani G, Calzavara-Pinton P. Topical treatment for the management of mild-to-moderate psoriasis: a critical appraisal of the current literature. Dermatol Ther (Heidelb). 2023;13(11):2527\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1763_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003931","author":"L Cai","year":"2026","unstructured":"Cai L, Zhang F, Zhang G, et\u00a0al. Superior efficacy and comparable safety of calcipotriol plus betamethasone dipropionate foam versus ointment in Chinese patients with plaque psoriasis: a randomized phase 3 trial. Chin Med J (Engl). 2026. https:\/\/doi.org\/10.1097\/CM9.0000000000003931.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"1763_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3109\/09546634.2015.1083935","volume":"27","author":"J Koo","year":"2016","unstructured":"Koo J, Tyring S, Werschler WP, et\u00a0al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris \u2013 A randomized phase II study. J Dermatolog Treat. 2016;27(2):120\u20137.","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"1763_CR16","first-page":"1468","volume":"14","author":"C Leonardi","year":"2015","unstructured":"Leonardi C, Bagel J, Yamauchi P, et\u00a0al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris - A randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468\u201377.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1763_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/jdv.13859","volume":"31","author":"C Paul","year":"2017","unstructured":"Paul C, Stein Gold L, Cambazard F, et\u00a0al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31(1):119\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1763_CR18","first-page":"119","volume":"15","author":"A Menter","year":"2017","unstructured":"Menter A, Gold LS, Koo J, et\u00a0al. Fixed-combination calcipotriene plus betamethasone dipropionate aerosol foam is well tolerated in patients with psoriasis vulgaris: pooled data from three randomized controlled studies. Skinmed. 2017;15(2):119\u201324.","journal-title":"Skinmed"},{"issue":"Suppl 2","key":"1763_CR19","doi-asserted-by":"publisher","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","volume":"64","author":"SR Feldman","year":"2005","unstructured":"Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65-68.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1763_CR20","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s11136-013-0384-y","volume":"22","author":"JC Cappelleri","year":"2013","unstructured":"Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the Physician Global Assessment Scale for assessing severity of psoriasis disease activity. Qual Life Res. 2013;22(9):2489\u201399.","journal-title":"Qual Life Res"},{"issue":"5","key":"1763_CR21","first-page":"997","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997\u20131035.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1763_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3109\/09546634.2012.742950","volume":"24","author":"DM Bushnell","year":"2013","unstructured":"Bushnell DM, Martin ML, McCarrier K, et\u00a0al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013;24(5):356\u201360.","journal-title":"J Dermatolog Treat"},{"key":"1763_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/9780470316696","volume-title":"Multiple imputation for nonresponse in surveys","author":"DB Rubin","year":"1987","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. 1 edn. Hoboken: John Wiley and Sons \u2013 Books; 1987.","edition":"1 edn"},{"issue":"49","key":"1763_CR24","doi-asserted-by":"publisher","DOI":"10.21105\/joss.02017","volume":"5","author":"J Brunson","year":"2020","unstructured":"Brunson J, Brunson JC. ggalluvial: layered grammar for alluvial plots. J Open Source Softw. 2020;5(49):2017.","journal-title":"J Open Source Softw"},{"issue":"1","key":"1763_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"issue":"3","key":"1763_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s13555-016-0125-6","volume":"6","author":"M Lind","year":"2016","unstructured":"Lind M, Nielsen KT, Schefe LH, et\u00a0al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther. 2016;6(3):413\u201325.","journal-title":"Dermatol Ther"},{"issue":"2","key":"1763_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.adengl.2019.01.001","volume":"110","author":"L Puig","year":"2019","unstructured":"Puig L, Carretero G. Update on topical treatments for psoriasis: the role of calcipotriol plus betamethasone dipropionate aerosol foam. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 2019;110(2):115\u201323.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"issue":"8","key":"1763_CR28","doi-asserted-by":"publisher","first-page":"822","DOI":"10.36849\/JDD.5743","volume":"20","author":"K Veverka","year":"2021","unstructured":"Veverka K, Hansen J, Yaloumis M, et\u00a0al. Calcipotriene plus betamethasone dipropionate foam for mild psoriasis: pooled results from three randomized trials. J Drugs Dermatol. 2021;20(8):822\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"1763_CR29","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/1346-8138.16519","volume":"49","author":"SJ Jo","year":"2022","unstructured":"Jo SJ, Park CJ, Bang CH, et\u00a0al. Calcipotriol\/betamethasone aerosol foam (Enstilum) for the topical treatment of psoriasis vulgaris in routine practice in Korea: a prospective, noninterventional multicenter study of treatment outcomes and patient satisfaction. J Dermatol. 2022;49(11):1085\u201395.","journal-title":"J Dermatol"},{"issue":"8","key":"1763_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.36849\/JDD.2020.5300","volume":"19","author":"L Kircik","year":"2020","unstructured":"Kircik L, Stein Gold L, Teng J, et\u00a0al. Fixed combination calcipotriene and betamethasone dipropionate (cal\/bd) foam for beyond-mild psoriasis: a possible alternative to systemic medication. J Drugs Dermatol. 2020;19(8):723\u201332.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1763_CR31","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s13555-021-00600-1","volume":"11","author":"R Aschoff","year":"2021","unstructured":"Aschoff R, Bewley A, Dattola A, et\u00a0al. Beyond-mild psoriasis: a consensus statement on calcipotriol and betamethasone dipropionate foam for the topical treatment of adult patients. Dermatol Ther. 2021;11(5):1791\u2013804.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1763_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1159\/000486700","volume":"233","author":"S Gerdes","year":"2018","unstructured":"Gerdes S, Krakor M, Anger T, Hutt HJ, Korber A. Prospective, observational, non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol\/betamethasone aerosol foam (Enstilar(r)) in patients with plaque psoriasis under daily practice conditions. Dermatology. 2018;233(6):425\u201334.","journal-title":"Dermatology"},{"issue":"9","key":"1763_CR33","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.adengl.2019.07.022","volume":"110","author":"M Velasco","year":"2019","unstructured":"Velasco M, Gonz\u00e1lez-Fern\u00e1ndez D, Rodriguez-Mart\u00edn M, S\u00e1nchez-Rega\u00f1a M, P\u00e9rez-Barrio S. Patient and physician satisfaction with calcipotriol and betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis on the body. Actas Dermo-Sifiliogr\u00e1ficas (English Edition). 2019;110(9):752\u20138.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"issue":"5","key":"1763_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15077","volume":"34","author":"A Campanati","year":"2021","unstructured":"Campanati A, Atzori L, Potenza C, et\u00a0al. Patient satisfaction with calcipotriol\/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: the LION real-life multicenter prospective observational cohort study. Dermatol Ther. 2021;34(5):e15077.","journal-title":"Dermatol Ther"},{"issue":"12","key":"1763_CR35","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1111\/jdv.17593","volume":"35","author":"D Rigopoulos","year":"2021","unstructured":"Rigopoulos D, Lazaridou E, Papadavid E, et\u00a0al. Patient-reported outcomes with calcipotriol\/betamethasone aerosol foam in patients with plaque psoriasis in Greece. Results from the CELSUS study. J Eur Acad Dermatol Venereol. 2021;35(12):e931\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1763_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/dth\/7529636","volume":"2025","author":"T Torres","year":"2025","unstructured":"Torres T, Martorell A, Leal Filipe P, et\u00a0al. Real\u2010world impact of calcipotriol\/betamethasone dipropionate aerosol foam on quality of life in patients with plaque psoriasis: a prospective observational study. Dermatol Ther. 2025;2025(1):Article ID 7529636.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1763_CR37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jdv.17673","volume":"36","author":"A Jalili","year":"2022","unstructured":"Jalili A, Calzavara-Pinton P, Kircik L, et\u00a0al. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal\/BD foam: a post-hoc analysis of PSO-LONG. J Eur Acad Dermatol Venereol. 2022;36(1):60\u20137.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01763-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:54:11Z","timestamp":1780584851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01763-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01763-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jianzhong Zhang has received consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer Investment Co. Ltd., Novartis Pharmaceuticals (China), Sanofi China, LEO Pharma (Shanghai) Co. Ltd., GSK (China) Investment Co. Ltd., Eli Lilly and Company (China), Xi\u2019an Jansen Pharmaceutical Ltd., Bristol-Myers Squibb (China) Investment Co. Ltd., Beijing Wenfeng Tianji Pharma Ltd., Keymed Biosciences (Chengdu) Ltd., Akeso Biopharma Co. Ltd., and Kintor Pharmaceutical Ltd. Adam El Mongy J\u00f8rgensen is an employee of LEO Pharma A\/S; Merle Kurvits and Jens Strodl Andersen are shareholders and employees of LEO Pharma A\/S. Lin Cai, Furen Zhang, Guoqiang Zhang, Yangfeng Ding, Yan Zhou, Shanshan Li, Juan Tao, Wei Yan, Rong Xiao, Bin Yang, Jianjun Qiao, Xiaoyong Man, and Zaixing Wang have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"At each investigational site, an independent ethics committee reviewed and approved the clinical trial  protocol and informed consent form. The Ethical Review Committee of Peking University People\u2019s Hospital provided the principal approval; the names of the remaining ethics committees are provided in Supplementary Table\n                      \n                      . The trial was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice, with the patients\u2019 understanding and written informed consent. There was no patient or public involvement in the design, conduct, or reporting of the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}